AngioDynamics Inc reported fiscal 2026 revenue of $320.17M, up 9.5% from $292.5M a year earlier, while the company recorded a net loss of ($36.74M) and diluted loss per share of ($0.88) for the year — a slightly larger loss versus fiscal 2025. This summary is based on the company's Form 10-K for the year ended 2026.
Financial Highlights
| MetricCurrent yearPrior yearYoY change | Revenue¹$320.17M$292.5M9.5% | Net income²($36.74M)($33.99M)(8.1%) | Diluted EPS³($0.88)($0.83)(6%) |
¹ Reported as “Net sales”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per share”.
Business Highlights
- Revenue growth of 9.5% was driven by Med Tech (up 18.4%) with modest gains in Med Device.
- Management is restructuring manufacturing to outsource most production while retaining select operations in Queensbury, targeting approximately $15M of annual savings.
- Product momentum came from Auryon, NanoKnife and the thrombus platform, supported by new IDEs, FDA clearances and published clinical data.
- Commercial execution improvements — including enhanced sales and physician training and targeted marketing — supported U.S. and international penetration.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.